GlassScriptPhysician profile
Gregory P Hanes
NPI 1255342994
$255,142.76
in general payments reported to CMS, 2019-2025
63 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $33K · 2021: $43K · 2022: $26K · 2023: $22K · 2024: $41K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Consulting Fee: $9,763 · Food and Beverage: $9,134 · Travel and Lodging: $7,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,316.50 |
| Consulting Fee | $9,762.50 |
| Food and Beverage | $9,133.75 |
| Travel and Lodging | $7,124.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $127,129.18 | 2019-2022 | |
| Abbvie INC. | $113,145.01 | 2019-2025 | |
| Argenx US, INC. | $3,456.10 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $1,829.81 | 2019-2025 | |
| Janssen Research & Development, LLC | $924.14 | 2023 | |
| Ucb, INC. | $629.14 | 2019-2025 | Fintepla, Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $539.88 | 2019-2025 | Ultomiris |
| Acorda Therapeutics, INC | $498.41 | 2019-2024 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $470.50 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $456.58 | 2019-2025 | Uplizna |
| Eisai INC. | $398.37 | 2020-2025 | |
| Ge Healthcare | $395.09 | 2019-2025 | |
| Pfizer INC. | $390.95 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $382.71 | 2019-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $382.50 | 2021-2025 | Hyqvia, Gammagard |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.